PHIO vs. ANVS, EYEN, MDCX, NBRV, APLT, PLUR, PRLD, MURA, ATNM, and SCLX
Should you be buying Phio Pharmaceuticals stock or one of its competitors? The main competitors of Phio Pharmaceuticals include Annovis Bio (ANVS), Eyenovia (EYEN), Medicus Pharma (MDCX), Nabriva Therapeutics (NBRV), Applied Therapeutics (APLT), Pluri (PLUR), Prelude Therapeutics (PRLD), Mural Oncology (MURA), Actinium Pharmaceuticals (ATNM), and Scilex (SCLX). These companies are all part of the "pharmaceutical products" industry.
Phio Pharmaceuticals vs. Its Competitors
Phio Pharmaceuticals (NASDAQ:PHIO) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.
Phio Pharmaceuticals has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500.
Phio Pharmaceuticals currently has a consensus target price of $14.00, indicating a potential upside of 506.06%. Annovis Bio has a consensus target price of $18.00, indicating a potential upside of 561.76%. Given Annovis Bio's higher possible upside, analysts clearly believe Annovis Bio is more favorable than Phio Pharmaceuticals.
In the previous week, Phio Pharmaceuticals had 2 more articles in the media than Annovis Bio. MarketBeat recorded 2 mentions for Phio Pharmaceuticals and 0 mentions for Annovis Bio. Phio Pharmaceuticals' average media sentiment score of 0.93 beat Annovis Bio's score of 0.00 indicating that Phio Pharmaceuticals is being referred to more favorably in the media.
Annovis Bio is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
57.3% of Phio Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 0.6% of Phio Pharmaceuticals shares are owned by insiders. Comparatively, 20.8% of Annovis Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Phio Pharmaceuticals' return on equity of -105.65% beat Annovis Bio's return on equity.
Summary
Phio Pharmaceuticals beats Annovis Bio on 7 of the 13 factors compared between the two stocks.
Get Phio Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PHIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Phio Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:PHIO) was last updated on 7/14/2025 by MarketBeat.com Staff
Free PHIO Stock Alerts